- Several data readouts of HB-200 alone and in combination with KEYTRUDA for treatment of HPV16+ HNSCC patients are expected in 2022.
- An amended agreement with Gilead Sciences, for arenavirus platform to develop treatments for HIV and HBV, established $54 million in commitment cash.
- An IND-filing of HB-300 for the treatment of patients with prostate cancer is expected in Q3 of 2022.
- HB-700 is another drug in the pipeline which is being advanced to treat several KRAS Mutated cancers such as: colorectal, pancreatic and lung cancers.
For further details see:
Hookipa: Speculative Biotech With Key Catalysts In 2022